ZB

Zura Bio Limited

ZURA·NASDAQ

$4.10

-5.9%
HealthcareBiotechnology

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$266.59M
EPS-1.0600
P/E Ratio-4.97
Earnings Date08/13/2026

zura

Other Current Assets

Last Annual Value

2.90M

3-Year CAGR

148%

5-Year CAGR

%

10-Year CAGR

%

ZB

Zura Bio Limited Competitors Analysis of Other Current Assets

ZURA · NASDAQ
CompanyOther Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
2.90M
40.9%N/AN/A 
4.55M
2.1%23.9%N/A
2.91M
33.7%34.1%N/A
746.89K
-8.4%N/AN/A
3.32M
221.3%161.8%44.3%
10.55M
-4.0%N/AN/A
1.86M
144.6%N/AN/A
3.41M
-0.0%N/AN/A
5.04M
63.3%4.4%N/A
3.28M
102.2%16.8%N/A
5.47M
16.1%N/AN/A
ZB

Zura Bio Limited Fair Value Envelope

ZURA · NASDAQ

Our analysis suggests that ZURA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.1, this represents a potential HIDDEN relative to our calculated worth for Zura Bio Limited.

Intrinsic Value
Current Price: $4.1